The Diagnosis of Normocalcaemic Hyperparathyroidism is Strikingly Dissimilar Using Different Commercial Laboratory Assays
Horm Metab Res 2022; 54: 429-434 DOI: 10.1055/a-1856-4900We assessed the impact of intact parathyroid hormone (iPTH) and adjusted calcium
analyses on Abbott, Roche and Siemens analytical platforms in the diagnosis of
normocalcaemic primary hyperparathyroidism (NCPHPT). These assays are used by
over 85% of clinical laboratories in the UK. Over five months,
consecutive serum samples from outpatients with NCPHPT in the laboratory with
Abbott assays were identified, aliquoted and stored at –80°C.
Frozen aliquots were transported monthly to the other two laboratories. After
thawing, samples were mixed and analysed immediately for calcium, albumin and
iPTH in the laboratories with Abbott, Roche and Siemens analytical platforms.
Adjusted calcium was calculated using the equation used in the respective
laboratory. Diagnostic concordance of iPTH and adjusted calcium were assessed
using manufacturer-provided assay-specific reference intervals and the pathology
harmony reference interval respectively. Fifty-five patients with NCPHPT were
identified using Abbott assays. Of these, 16 (29.1%) and 11
(20.0%) had NCPHPT, 9 (16.4%) and 13 (23.6%) had
hypercalcaemic primary hyperparathyroidism, and 30 (54.6%) and 31
(56.4%) patients had normal results when analysed in laboratories with
Roche and Siemens assays, respectively...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Kalaria, Tejas Fenn, Jonathan Sanders, Anna Yates, Alexandra Duff, Christopher Ashby, Helen Mohammed, Pervaz Ford, Clare Gama, Rousseau Tags: Original Article: Endocrine Care Source Type: research
More News: Calcium | Endocrinology | Hormones | Hyperparathyroidism | Laboratory Medicine | Pathology | Study